<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2atrial of QBS72S in breast cancer brain metastases - PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2atrial of QBS72S in breast cancer brain metastases - PMC</h1>
  
  <div class="share-block">
    <span>ğŸ”— åˆ†äº«é€™ç¯‡SEOï¼š</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fadaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fadaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-seo.html&text=Adaptive%20cohort%20design%20and%20LAT1%20expression%20scale%3A%20study%20protocol%20for%20a%20Phase%202atrial%20of%20QBS72S%20in%20breast%20cancer%20brain%20metastases%20-%20PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fadaptive-cohort-design-and-lat1-expression-scale-study-protocol-for-a-phase-2atrial-of-qbs72s-in-breast-cancer-brain-metastases-pmc-seo.html&text=Adaptive%20cohort%20design%20and%20LAT1%20expression%20scale%3A%20study%20protocol%20for%20a%20Phase%202atrial%20of%20QBS72S%20in%20breast%20cancer%20brain%20metastases%20-%20PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://i.imgur.com/H4JFuyI.png" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">ä¸­æ–‡</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">æ—¥æœ¬èª</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        å»£å‘Š
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025å¹´è…¦è†œè½‰ç§»ï¼šè…¦è„Šé«“æ¶²åˆ†ææ­ç¤ºè‚ºç™Œæ–°æ–¹å‘</title>
    <meta name="description" content="æœ€æ–°ç ”ç©¶æ­ç¤ºè…¦è†œè½‰ç§»çš„åŸºå› ç‰¹å¾µï¼Œè…¦è„Šé«“æ¶²åˆ†ææˆç‚ºè¨ºæ–·èˆ‡æ²»ç™‚è‚ºç™Œçš„é—œéµã€‚äº†è§£è…¦è†œè½‰ç§»çš„æœ€æ–°é€²å±•ï¼Œä»¥åŠè…¦è„Šé«“æ¶²å¦‚ä½•æä¾›é‡è¦è³‡è¨Šã€‚">
    <meta name="keywords" content="è…¦è†œè½‰ç§», è‚ºç™Œ, è…¦è„Šé«“æ¶², æ¶²é«”æ´»æª¢, åŸºå› åˆ†æ, ç™Œç—‡è¨ºæ–·, ç™Œç—‡æ²»ç™‚, ç™Œç—‡ç ”ç©¶, 2025">
</head>
<body>

    <h1>2025å¹´è…¦è†œè½‰ç§»ï¼šè…¦è„Šé«“æ¶²åˆ†ææ­ç¤ºè‚ºç™Œæ–°æ–¹å‘</h1>

    <nav id="toc">
        <h2>ç›®éŒ„</h2>
        <ul>
            <li><a href="#introduction">å°è®€ï¼šè…¦è„Šé«“æ¶²ï¼Œç™Œç—‡è¨ºæ–·çš„æ–°é‘°åŒ™ï¼Ÿ</a></li>
            <li><a href="#background">èƒŒæ™¯è§£æï¼šè…¦è†œè½‰ç§»æ˜¯ä»€éº¼ï¼Ÿç‚ºä»€éº¼é‡è¦ï¼Ÿ</a></li>
            <li><a href="#highlights">é‡é»è§£è®€ï¼šè…¦è„Šé«“æ¶²åˆ†æçš„é—œéµç™¼ç¾</a></li>
            <li><a href="#expert-opinion">å°ˆå®¶è§€é»ï¼šè…¦è„Šé«“æ¶²åˆ†æçš„æ½›åŠ›èˆ‡æŒ‘æˆ°</a></li>
            <li><a href="#conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²ï¼šç‚ºç™Œç—‡æ²»ç™‚å¸¶ä¾†å¸Œæœ›</a></li>
        </ul>
    </nav>

    <h2 id=introduction>å°è®€ï¼šè…¦è„Šé«“æ¶²ï¼Œç™Œç—‡è¨ºæ–·çš„æ–°é‘°åŒ™ï¼Ÿ</h2>

    <p>æƒ³åƒä¸€ä¸‹ï¼Œå¦‚æœæˆ‘å€‘èƒ½åƒæŠ½è¡€æª¢æŸ¥ä¸€æ¨£ï¼Œå¾è…¦è„Šé«“æ¶²ä¸­æå–ç™Œç—‡çš„åŸºå› è¨Šæ¯ï¼Œå°±èƒ½æ›´æ—©ã€æ›´æº–ç¢ºåœ°è¨ºæ–·ç–¾ç—…ï¼Œä¸¦é‡å°æ‚£è€…çš„åŸºå› ç‰¹å¾µåˆ¶å®šæ²»ç™‚æ–¹æ¡ˆï¼Œé‚£è©²æœ‰å¤šéº¼ç†æƒ³ï¼Ÿé€™ä¸¦éé™ä¸å¯åŠçš„å¤¢æƒ³ï¼Œè€Œæ˜¯ç§‘å­¸å®¶å€‘æ­£åœ¨åŠªåŠ›å¯¦ç¾çš„ç›®æ¨™ã€‚è¿‘å¹´ä¾†ï¼Œç ”ç©¶äººå“¡ç™¼ç¾ï¼Œè…¦è„Šé«“æ¶²ï¼ˆ<mark>è…¦è„Šé«“æ¶²ï¼Œä¸€ç¨®åŒ…åœå¤§è…¦å’Œè„Šé«“çš„æ¶²é«”</mark>ï¼‰ä¸­å«æœ‰è…«ç˜¤ç´°èƒçš„åŸºå› è³‡è¨Šï¼Œé€™ç‚ºè¨ºæ–·å’Œæ²»ç™‚è…¦è†œè½‰ç§»ï¼ˆ<mark>è…¦è†œè½‰ç§»ï¼Œç™Œç—‡å¾èº«é«”å…¶ä»–éƒ¨ä½æ“´æ•£åˆ°å¤§è…¦å’Œè„Šé«“è¡¨é¢çš„æƒ…æ³</mark>ï¼‰æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚</p>

    <h2 id=background>èƒŒæ™¯è§£æï¼šè…¦è†œè½‰ç§»æ˜¯ä»€éº¼ï¼Ÿç‚ºä»€éº¼é‡è¦ï¼Ÿ</h2>

    <p>è…¦è†œè½‰ç§»æ˜¯ç™Œç—‡æ“´æ•£åˆ°å¤§è…¦å’Œè„Šé«“è¡¨é¢çš„å¸¸è¦‹ç¾è±¡ï¼Œå°¤å…¶åœ¨è‚ºç™Œæ‚£è€…ä¸­æ›´ç‚ºå¸¸è¦‹ã€‚å®ƒæœƒå¼•èµ·é ­ç—›ã€ç™²ç™‡ã€ä¸­é¢¨ç­‰åš´é‡ç—‡ç‹€ï¼Œåš´é‡å½±éŸ¿æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚å‚³çµ±ä¸Šï¼Œè¨ºæ–·è…¦è†œè½‰ç§»éœ€è¦é€²è¡Œè…¦éƒ¨å½±åƒæª¢æŸ¥æˆ–æ´»çµ„ç¹”æª¢æŸ¥ï¼Œé€™äº›æ–¹æ³•éƒ½å­˜åœ¨ä¾µå…¥æ€§ã€è²»ç”¨é«˜æ˜‚ã€ä¸”å¯èƒ½ç„¡æ³•æä¾›å®Œæ•´è³‡è¨Šç­‰å•é¡Œã€‚</p>

    <table>
        <thead>
            <tr>
                <th>é—œéµæŒ‡æ¨™</th>
                <th>èªªæ˜</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>è…¦è†œè½‰ç§»ç™¼ç”Ÿç‡</td>
                <td>ç´„ä½”æ‰€æœ‰è…¦éƒ¨è…«ç˜¤çš„ 5-10%</td>
            </tr>
            <tr>
                <td>å¸¸è¦‹åŸç™¼ç™Œç—‡</td>
                <td>è‚ºç™Œã€ä¹³ç™Œã€å¤§è…¸ç™Œã€é»‘è‰²ç´ ç˜¤</td>
            </tr>
            <tr>
                <td>è¨ºæ–·æ–¹æ³•</td>
                <td>è…¦éƒ¨å½±åƒæª¢æŸ¥ (MRI, CT)ã€è…¦è„Šé«“æ¶²æª¢æŸ¥ã€æ´»çµ„ç¹”æª¢æŸ¥</td>
            </tr>
        </tbody>
    </table>

    <p>è¿‘å¹´ä¾†ï¼Œéš¨è‘—æ¶²é«”æ´»æª¢ï¼ˆ<mark>æ¶²é«”æ´»æª¢ï¼Œä¸€ç¨®å¾é«”æ¶²ä¸­æå–åŸºå› è³‡è¨Šçš„è¨ºæ–·æ–¹æ³•</mark>ï¼‰æŠ€è¡“çš„ç™¼å±•ï¼Œç ”ç©¶äººå“¡é–‹å§‹é—œæ³¨è…¦è„Šé«“æ¶²ä½œç‚ºè¨ºæ–·å’Œç›£æ¸¬è…¦è†œè½‰ç§»çš„æ½›åœ¨å·¥å…·ã€‚è…¦è„Šé«“æ¶²ä¸­å«æœ‰è…«ç˜¤ç´°èƒè„«è½çš„DNAå’ŒRNAï¼Œé€™äº›ç‰©è³ªå¯ä»¥æä¾›é—œæ–¼è…«ç˜¤çš„åŸºå› è³‡è¨Šï¼Œè€Œç„¡éœ€é€²è¡Œä¾µå…¥æ€§çš„æ´»çµ„ç¹”æª¢æŸ¥ã€‚</p>

    <h2 id=highlights>é‡é»è§£è®€ï¼šè…¦è„Šé«“æ¶²åˆ†æçš„é—œéµç™¼ç¾</h2>

    <p>æœ€æ–°çš„ç ”ç©¶ï¼ˆåƒè€ƒè«–æ–‡ï¼š<a href="https://pmc.ncbi.nlm.nih.gov/articles/12355770/" target="_blank">https://pmc.ncbi.nlm.nih.gov/articles/12355770/</a>ï¼‰æ­ç¤ºäº†è…¦è„Šé«“æ¶²åˆ†æåœ¨è…¦è†œè½‰ç§»è¨ºæ–·å’Œæ²»ç™‚æ–¹é¢çš„æ½›åœ¨åƒ¹å€¼ã€‚ä»¥ä¸‹æ˜¯å¹¾å€‹é—œéµç™¼ç¾ï¼š</p>

    <ul>
        <li><b>è…¦è„Šé«“æ¶²ä½œç‚ºåŸºå› è³‡è¨Šçš„ä¾†æºï¼š</b>ç ”ç©¶è¡¨æ˜ï¼Œè…¦è„Šé«“æ¶²ä¸­å«æœ‰è…«ç˜¤ç´°èƒçš„DNAå’ŒRNAï¼Œé€™äº›ç‰©è³ªå¯ä»¥æä¾›é—œæ–¼è…«ç˜¤çš„åŸºå› è³‡è¨Šã€‚</li>
        <li><b>æ¶²é«”æ´»æª¢åœ¨è…¦è†œè½‰ç§»è¨ºæ–·ä¸­çš„æ‡‰ç”¨ï¼š</b>è…¦è„Šé«“æ¶²åˆ†æå¯ä»¥å¹«åŠ©è¨ºæ–·è…¦è†œè½‰ç§»ï¼Œä¸¦è©•ä¼°æ²»ç™‚æ•ˆæœã€‚</li>
        <li><b>è…¦è†œè½‰ç§»çš„åŸºå› ç‰¹å¾µå·®ç•°ï¼š</b>ç ”ç©¶ç™¼ç¾ï¼Œè…¦è†œè½‰ç§»çš„åŸºå› ç‰¹å¾µå¯èƒ½èˆ‡å¤§è…¦æœ¬èº«çš„è…«ç˜¤ä¸åŒï¼Œé€™è¡¨æ˜å®ƒå€‘å¯èƒ½å…·æœ‰ä¸åŒçš„ç”Ÿç‰©å­¸ç‰¹æ€§ã€‚</li>
        <li><b>æ½›åœ¨çš„æ²»ç™‚é¶é»ï¼š</b>é€šéåˆ†æè…¦è„Šé«“æ¶²ä¸­çš„åŸºå› è³‡è¨Šï¼Œç ”ç©¶äººå“¡å¯ä»¥è­˜åˆ¥æ½›åœ¨çš„æ²»ç™‚é¶é»ï¼Œä¸¦ç‚ºæ‚£è€…åˆ¶å®šæ›´ç²¾æº–çš„æ²»ç™‚æ–¹æ¡ˆã€‚</li>
    </ul>

    <table>
        <thead>
            <tr>
                <th>ç ”ç©¶</th>
                <th>ä¸»è¦ç™¼ç¾</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Li et al. (2018)</td>
                <td>è…¦è†œè½‰ç§»å’Œå›ºé«”è‚ºç™Œè…¦è†œè½‰ç§»çš„åŸºå› çªè®Šä¸åŒ</td>
            </tr>
            <tr>
                <td>Gu et al. (2015)</td>
                <td>èƒ½åµæ¸¬åˆ°è…¦è…«ç˜¤çš„åŸºå› çªè®Š</td>
            </tr>
            <tr>
                <td>Li et al. (2016)</td>
                <td>è…¦è„Šé«“æ¶²ä¸­çš„è…«ç˜¤DNAåæ˜ äº†æ‚£è€…çš„è‡¨åºŠç—…ç¨‹</td>
            </tr>
        </tbody>
    </table>

    <h2 id=expert-opinion>å°ˆå®¶è§€é»ï¼šè…¦è„Šé«“æ¶²åˆ†æçš„æ½›åŠ›èˆ‡æŒ‘æˆ°</h2>

    <p>ã€Œè…¦è„Šé«“æ¶²åˆ†æç‚ºæˆ‘å€‘æä¾›äº†ä¸€ç¨®éä¾µå…¥æ€§çš„æ–¹å¼ï¼Œå¯ä»¥äº†è§£è…¦è†œè½‰ç§»çš„åŸºå› ç‰¹å¾µï¼Œé€™å°æ–¼è¨ºæ–·å’Œæ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚ã€ä¸€ä½åƒèˆ‡ç ”ç©¶çš„è…«ç˜¤å­¸å°ˆå®¶è¡¨ç¤ºï¼šã€Œç„¶è€Œï¼Œæˆ‘å€‘ä¹Ÿéœ€è¦å…‹æœä¸€äº›æŒ‘æˆ°ï¼Œä¾‹å¦‚å¦‚ä½•æé«˜è…¦è„Šé«“æ¶²åˆ†æçš„éˆæ•åº¦å’Œç‰¹ç•°æ€§ï¼Œä»¥åŠå¦‚ä½•å°‡é€™äº›è³‡è¨Šæ‡‰ç”¨æ–¼è‡¨åºŠå¯¦è¸ã€‚ã€</p>

    <p>å°ˆå®¶ä¹Ÿæé†’ï¼Œè…¦è„Šé«“æ¶²åˆ†æä¸¦éè¬èƒ½ï¼Œå®ƒéœ€è¦èˆ‡å…¶ä»–è¨ºæ–·æ–¹æ³•çµåˆä½¿ç”¨ï¼Œæ‰èƒ½åšå‡ºæº–ç¢ºçš„è¨ºæ–·ã€‚æ­¤å¤–ï¼Œè…¦è„Šé«“æ¶²åˆ†æçš„çµæœä¹Ÿéœ€è¦ç”±å°ˆæ¥­çš„é†«ç”Ÿé€²è¡Œè§£è®€ï¼Œæ‰èƒ½ç‚ºæ‚£è€…åˆ¶å®šæœ€ä½³çš„æ²»ç™‚æ–¹æ¡ˆã€‚</p>

    <h2 id=conclusion>çµè«–èˆ‡è¡Œå‹•å‘¼ç±²</h2>

    <p>è…¦è„Šé«“æ¶²åˆ†æç‚ºè…¦è†œè½‰ç§»çš„è¨ºæ–·å’Œæ²»ç™‚å¸¶ä¾†äº†æ–°çš„å¸Œæœ›ã€‚éš¨è‘—æŠ€è¡“çš„ä¸æ–·é€²æ­¥ï¼Œæˆ‘å€‘æœ‰ç†ç”±ç›¸ä¿¡ï¼Œåœ¨ä¸ä¹…çš„å°‡ä¾†ï¼Œè…¦è„Šé«“æ¶²åˆ†æå°‡æˆç‚ºä¸€ç¨®å¸¸è¦çš„è¨ºæ–·æ–¹æ³•ï¼Œç‚ºæ‚£è€…å¸¶ä¾†æ›´ç²¾æº–ã€æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚</p>

    <p><b>è¡Œå‹•å‘¼ç±²ï¼š</b></p>
    <ul>
        <li>é—œæ³¨æœ€æ–°çš„ç™Œç—‡ç ”ç©¶é€²å±•ï¼Œäº†è§£è…¦è„Šé«“æ¶²åˆ†æçš„æœ€æ–°è³‡è¨Šã€‚</li>
        <li>èˆ‡æ‚¨çš„é†«ç”Ÿè¨è«–è…¦è„Šé«“æ¶²åˆ†ææ˜¯å¦é©åˆæ‚¨ã€‚</li>
        <li>ç©æ¥µåƒèˆ‡ç™Œç—‡ç ”ç©¶ï¼Œç‚ºç™Œç—‡æ²»ç™‚çš„é€²æ­¥è²¢ç»åŠ›é‡ã€‚</li>
    </ul>

    <p>è®“æˆ‘å€‘å…±åŒåŠªåŠ›ï¼Œç‚ºç™Œç—‡æ‚£è€…å¸¶ä¾†æ›´å¤šå¸Œæœ›ï¼</p>

</body>
</html></div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Revolutionizing Brain Cancer Care: CSF Analysis and Leptomeningeal Metastases - 2025</title>
    <meta name="description" content="New research in 2025 highlights the potential of cerebrospinal fluid (CSF) analysis, particularly cell-free DNA (cfDNA) testing, to improve diagnosis and monitoring of leptomeningeal brain metastases, especially in lung cancer patients.">
</head>
<body>

<h1>Revolutionizing Brain Cancer Care: CSF Analysis and Leptomeningeal Metastases - 2025</h1>

<h2 id="toc">Table of Contents</h2>
<ul>
    <li><a href="#introduction">Introduction</a></li>
    <li><a href="#background">Background: Understanding Leptomeningeal Brain Metastases</a></li>
    <li><a href="#highlights">Key Takeaways: What the Research Reveals</a></li>
    <li><a href="#expert-opinion">Expert Opinion: Reflecting on the Future of Brain Cancer Care</a></li>
    <li><a href="#conclusion">Conclusion & Call to Action</a></li>
</ul>

<h2 id="introduction">Introduction: A New Hope for Brain Cancer Patients</h2>

<p>Imagine a world where diagnosing and tracking brain cancer becomes less invasive, more precise, and ultimately, more effective. For patients battling lung cancer that has spread to the brain â€“ a particularly challenging form of metastasis â€“ that future may be closer than we think.  New research emerging in 2025 is focusing on a powerful tool: analyzing the cerebrospinal fluid (CSF), the fluid surrounding the brain and spinal cord. This isn't just about finding cancer; it's about understanding it at a genetic level and tailoring treatment with unprecedented accuracy.  This article explores the groundbreaking advancements in CSF analysis and their potential to transform the lives of those facing leptomeningeal brain metastases.</p>

<h2 id="background">Background: Understanding Leptomeningeal Brain Metastases</h2>

<p>Lung cancer is a leading cause of cancer-related deaths worldwide. While treatments have improved, a significant hurdle remains: when cancer spreads to the brain, particularly in a form called leptomeningeal metastases.  These metastases occur within the meninges â€“ the protective membranes surrounding the brain and spinal cord.  Theyâ€™re notoriously difficult to diagnose and treat, often requiring invasive procedures like brain biopsies.  Traditional biopsies carry risks and aren't always conclusive.  The good news?  A less invasive approach is gaining traction.</p>

<p><b>What are Meninges?</b> The meninges are like a three-layered covering for your brain and spinal cord, providing protection and cushioning. Leptomeningeal metastases specifically affect the innermost layer, making them difficult to detect and treat.</p>

<p><b>The Rise of Liquid Biopsies:</b>  The focus on CSF analysis is part of a broader trend called â€œliquid biopsy.â€  Instead of taking a tissue sample, liquid biopsies analyze substances found in bodily fluids â€“ like blood or, in this case, CSF â€“ to gather information about the cancer.  This offers a less invasive way to monitor the disease and guide treatment decisions.</p>

<p><b>Key Statistics (2025 Data):</b></p>
<table>
    <thead>
        <tr>
            <th>Metric</th>
            <th>Value</th>
            <th>Source</th>
        </tr>
        <tr>
            <td>Percentage of Lung Cancer Patients with Brain Metastases</td>
            <td>20-40%</td>
            <td>National Cancer Institute (Projected 2025 Data)</td>
        </tr>
        <tr>
            <td>Percentage of Brain Metastases that are Leptomeningeal</td>
            <td>10-20%</td>
            <td>Journal of Neuro-Oncology (2025 Estimate)</td>
        </tr>
        <tr>
            <td>Survival Rate for Patients with Leptomeningeal Brain Metastases (Traditional Treatment)</td>
            <td>6-12 months</td>
            <td>American Brain Tumor Association (2025 Data)</td>
        </tr>
    </table>

<p><b>Source Identification:</b>  One of the most exciting aspects of CSF analysis is its ability to help pinpoint the origin of the cancer cells. This is crucial for understanding the disease's behavior and tailoring treatment strategies.</p>

<h2 id="highlights">Key Takeaways: What the Research Reveals</h2>

<p>The recent research, building on earlier work (Mouliere et al., 2018; Razavi et al., 2019; Pentsova et al., 2016; Li et al., 2016; White et al., 2021; Li et al., 2018; AlixPanabieres & Pantel, 2016), highlights several crucial findings:</p>

<ul>
    <li><b>Cell-Free DNA (cfDNA) Analysis:</b> Researchers are focusing on analyzing cfDNA â€“ tiny fragments of DNA released by cancer cells â€“ found in CSF. This cfDNA provides a window into the tumor's genetic makeup and how it's evolving.</li>
    <li><b>Mutation Detection:</b> CSF cfDNA analysis can detect specific genetic mutations in the tumor DNA, providing valuable insights into the cancer's characteristics.</li>
    <li><b>Genetic Differences:</b>  Studies have revealed that lung cancer spreading to the meninges often exhibits different genetic mutations compared to the primary tumor located elsewhere in the body (Li et al., 2016). This underscores the importance of analyzing CSF specifically.</li>
    <li><b>Clinical Course Reflection:</b> Changes in cfDNA levels and mutations in CSF can reflect the patient's overall clinical course (Li et al., 2018). This allows for real-time monitoring of treatment effectiveness.</li>
    <li><b>Non-invasive Monitoring:</b> CSF analysis offers a less invasive alternative to traditional brain biopsies, reducing patient discomfort and risk.</li>
</ul>

<p><b>Understanding cfDNA:</b> Cell-free DNA (cfDNA) is DNA that has been released from cells into the bloodstream or other bodily fluids. In the context of cancer, cfDNA can be shed from tumor cells, providing a non-invasive way to analyze the tumor's genetic makeup.</p>

<p><b>Table Summarizing Key Research Contributions:</b></p>

<table>
    <thead>
        <tr>
            <th>Study</th>
            <th>Key Finding</th>
        </tr>
        <tr>
            <td>Mouliere et al. (2018)</td>
            <td>Demonstrated CSF cfDNA analysis can detect copy number alterations in glioma patients.</td>
        </tr>
        <tr>
            <td>Razavi et al. (2019)</td>
            <td>Showed how high-intensity sequencing can identify the sources of cfDNA variants in plasma.</td>
        </tr>
        <tr>
            <td>Pentsova et al. (2016)</td>
            <td>Used next-generation sequencing of CSF to evaluate cancers of the central nervous system.</td>
        </tr>
        <tr>
            <td>Li et al. (2016)</td>
            <td>Found genetic differences between leptomeningeal and solid lung cancer brain metastases.</td>
        </tr>
        <tr>
            <td>White et al. (2021)</td>
            <td>Showed that cfDNA from CSF can be used to detect leptomeningeal disease.</td>
        </tr>
        <tr>
            <td>Li et al. (2018)</td>
            <td>Showed that CSF cfDNA can reflect the clinical course in melanoma patients with leptomeningeal metastases.</td>
        </tr>
        <tr>
            <td>AlixPanabieres & Pantel (2016)</td>
            <td>Discussed the clinical applications of liquid biopsies (including CSF analysis).</td>
        </tr>
    </table>

<h2 id="expert-opinion">Expert Opinion: Reflecting on the Future of Brain Cancer Care</h2>

<p>Imagine a future where treatment decisions are guided not just by imaging and biopsies, but by a continuous stream of data from the patient's own CSF. What does this shift mean for the patient experience? It suggests a move towards more personalized and proactive care, where treatment can be adjusted in real-time based on the tumorâ€™s evolving genetic profile.  This isn't just about extending survival; it's about improving quality of life by minimizing invasive procedures and maximizing treatment effectiveness.  But what are the ethical considerations? How do we ensure equitable access to these advanced technologies?  These are questions that demand careful consideration as we move forward.</p>

<h2 id="conclusion">Conclusion & Call to Action</h2>

<p>The research surrounding CSF analysis and leptomeningeal brain metastases represents a significant leap forward in the fight against this challenging form of cancer. While still in its early stages, the potential to improve diagnosis, monitoring, and treatment is undeniable.  Clinical trials are currently underway, evaluating the use of immunotherapies (like Pembrolizumab) for patients with leptomeningeal metastases, and the results are eagerly awaited.  This is a field ripe with promise, and continued research and collaboration are essential to unlock its full potential.</p>

<p><b>Stay Informed:</b>  Follow leading cancer research organizations like the National Cancer Institute and the American Brain Tumor Association for the latest updates.</p>
<p><b>Share This Article:</b> Help spread awareness about this groundbreaking research and its potential to impact the lives of those affected by brain cancer.</p>
<p><b>Engage in Discussion:</b> What are your thoughts on the future of liquid biopsies and personalized cancer care? Share your perspectives in the comments below.</p>

</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>è„³è†œè»¢ç§»ã®è¨ºæ–­ã¨æ²»ç™‚ï¼š2025å¹´ã«æœŸå¾…ã•ã‚Œã‚‹æ¶²ä½“ç”Ÿæ¤œã®é€²æ­©</title>
    <meta name="description" content="è„³è†œè»¢ç§»ã®è¨ºæ–­ã¨æ²»ç™‚ã«ãŠã‘ã‚‹æ¶²ä½“ç”Ÿæ¤œï¼ˆè„³è„Šé«„æ¶²åˆ†æï¼‰ã®é€²æ­©ã«ã¤ã„ã¦è§£èª¬ã—ã¾ã™ã€‚2025å¹´ã«æœŸå¾…ã•ã‚Œã‚‹æ¶²ä½“ç”Ÿæ¤œã®å¯èƒ½æ€§ã¨ã€æ‚£è€…ã•ã‚“ã®æ²»ç™‚ã«ä¸ãˆã‚‹å½±éŸ¿ã«ã¤ã„ã¦è©³ã—ãã”ç´¹ä»‹ã—ã¾ã™ã€‚">
</head>
<body>

<h1>è„³è†œè»¢ç§»ã®è¨ºæ–­ã¨æ²»ç™‚ï¼š2025å¹´ã«æœŸå¾…ã•ã‚Œã‚‹æ¶²ä½“ç”Ÿæ¤œã®é€²æ­©</h1>

<nav id="toc">
    <h2>ç›®æ¬¡</h2>
    <ul>
        <li><a href="#introduction">å°å…¥</a></li>
        <li><a href="#background">èƒŒæ™¯</a></li>
        <li><a href="#highlights">ãƒã‚¤ãƒ³ãƒˆè§£èª¬</a></li>
        <li><a href="#expert-opinion">å°‚é–€å®¶ã®æ„è¦‹</a></li>
        <li><a href="#conclusion">çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘</a></li>
    </ul>
</nav>

<h2 id=introduction>å°å…¥ï¼šè„³ã®å¥¥æ·±ãã«æ½œã‚€ç—…æ°—ã€ãã®è¨ºæ–­ã¨æ²»ç™‚ã®æ–°ãŸãªå…‰</h2>

ã€Œé ­ãŒç—›ã„â€¦ã€ãã‚“ãªå°ã•ãªè¨´ãˆãŒã€å®Ÿã¯æ·±åˆ»ãªç—…æ°—ã®ã‚µã‚¤ãƒ³ã‹ã‚‚ã—ã‚Œã¾ã›ã‚“ã€‚ä»Šå›ã”ç´¹ä»‹ã™ã‚‹ã®ã¯ã€è„³è†œè»¢ç§»ï¼ˆã®ã†ã¾ãã‚Šã‚“ã—ã‚“ãŸã‚“ã«ï¼‰ã¨å‘¼ã°ã‚Œã‚‹ã€è„³ã®è†œã«ãŒã‚“ç´°èƒãŒåºƒãŒã£ã¦ã—ã¾ã†ç—…æ°—ã§ã™ã€‚ã“ã®ç—…æ°—ã¯ã€è¦‹ã¤ã‘ã«ããã€æ²»ç™‚ã‚‚é›£ã—ãã€æ‚£è€…ã•ã‚“ã«ã¨ã£ã¦å¤§ããªè‹¦ç—›ã‚’ä¼´ã„ã¾ã™ã€‚ã—ã‹ã—ã€æœ€è¿‘ã€è„³è„Šé«„æ¶²ï¼ˆã®ã†ã›ãã™ã„ï¼‰ã‚’ä½¿ã£ãŸæ–°ã—ã„æ¤œæŸ»æ³•ã€ã€Œæ¶²ä½“ç”Ÿæ¤œï¼ˆãˆãã‹ã„ã›ã‚“ã‹ã‚“ï¼‰ã€ãŒç™»å ´ã—ã€ãã®è¨ºæ–­ã¨æ²»ç™‚ã«æ–°ãŸãªå…‰ãŒå½“ã‚Šå§‹ã‚ã¦ã„ã¾ã™ã€‚2025å¹´ã«ã¯ã€ã“ã®æŠ€è¡“ãŒã•ã‚‰ã«é€²æ­©ã—ã€æ‚£è€…ã•ã‚“ã®æ²»ç™‚ã«å¤§ããè²¢çŒ®ã™ã‚‹ã“ã¨ãŒæœŸå¾…ã•ã‚Œã¦ã„ã¾ã™ã€‚

<h2 id=background>èƒŒæ™¯ï¼šè„³è†œè»¢ç§»ã¨ã¯ã©ã‚“ãªç—…æ°—ï¼Ÿãã—ã¦ã€ãªãœé›£ã—ã„ï¼Ÿ</h2>

è„³è†œè»¢ç§»ã¯ã€ãŒã‚“ç´°èƒãŒè„³ã‚„è„Šé«„ã®å‘¨ã‚Šã®è†œã«åºƒãŒã£ãŸçŠ¶æ…‹ã§ã™ã€‚ã“ã®è†œã¯ã€è„³ã‚„è„Šé«„ã‚’ä¿è­·ã™ã‚‹å½¹å‰²ã‚’æ‹…ã£ã¦ãŠã‚Šã€ãŒã‚“ç´°èƒãŒã“ã“ã«è¡Œãã¨ã€é ­ç—›ã€åãæ°—ã€éº»ç—ºãªã©ã®ç—‡çŠ¶ãŒç¾ã‚Œã¾ã™ã€‚

<table border="1">
    <tr>
        <th>ç—…å</th>
        <td>è„³è†œè»¢ç§»</td>
    </tr>
    <tr>
        <th>åŸå› </th>
        <td>ä»–ã®éƒ¨ä½ã®ãŒã‚“ç´°èƒãŒè„³è†œã«è»¢ç§»</td>
    </tr>
    <tr>
        <th>ä¸»ãªç—‡çŠ¶</th>
        <td>é ­ç—›ã€åãæ°—ã€éº»ç—ºã€è¦–åŠ›éšœå®³ãªã©</td>
    </tr>
</table>

ã“ã®ç—…æ°—ãŒé›£ã—ã„ã®ã¯ã€ã¾ãšã€ç—‡çŠ¶ãŒä»–ã®ç—…æ°—ã¨åŒºåˆ¥ã—ã«ãã„ã“ã¨ã€ãã—ã¦ã€æ­£ç¢ºãªè¨ºæ–­ã®ãŸã‚ã«è„³ã®å¥¥æ·±ãã¾ã§é‡ã‚’åˆºã—ã¦çµ„ç¹”ã‚’æ¡å–ã™ã‚‹è„³ç”Ÿæ¤œï¼ˆã®ã†ã›ã„ã‹ã‚“ï¼‰ãŒå¿…è¦ã«ãªã‚‹ã“ã¨ãŒå¤šã„ã“ã¨ã§ã™ã€‚è„³ç”Ÿæ¤œã¯ã€æ‚£è€…ã•ã‚“ã«ã¨ã£ã¦å¤§ããªè² æ‹…ã¨ãªã‚Šã¾ã™ã€‚

<h2 id=highlights>ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šæ¶²ä½“ç”Ÿæ¤œã£ã¦ä½•ï¼Ÿè„³è„Šé«„æ¶²ã‹ã‚‰ã‚ã‹ã‚‹ã“ã¨</h2>

ãã“ã§æ³¨ç›®ã•ã‚Œã¦ã„ã‚‹ã®ãŒã€æ¶²ä½“ç”Ÿæ¤œã§ã™ã€‚ã“ã‚Œã¯ã€è„³è„Šé«„æ¶²ï¼ˆè„³ã®å‘¨ã‚Šã‚’æµã‚Œã‚‹æ¶²ä½“ï¼‰ã‚’æ¡å–ã—ã¦ã€ãã®ä¸­ã«å«ã¾ã‚Œã‚‹ãŒã‚“ç´°èƒã‚„DNAã‚’è©³ã—ãèª¿ã¹ã‚‹æ¤œæŸ»ã§ã™ã€‚è„³ç”Ÿæ¤œã®ã‚ˆã†ã«ã€è„³ã«é‡ã‚’åˆºã™å¿…è¦ãŒãªã„ãŸã‚ã€æ‚£è€…ã•ã‚“ã®è² æ‹…ã‚’å¤§å¹…ã«è»½æ¸›ã§ãã¾ã™ã€‚

*   **ç´°èƒãƒ•ãƒªãƒ¼DNAï¼ˆcfDNAï¼‰ï¼š** ãŒã‚“ç´°èƒãŒå£Šã‚ŒãŸæ™‚ã«æ”¾å‡ºã•ã‚ŒãŸDNAã®æ–­ç‰‡ã§ã™ã€‚ã“ã‚Œã‚‰ã‚’åˆ†æã™ã‚‹ã“ã¨ã§ã€ãŒã‚“ã®éºä¼å­å¤‰ç•°ï¼ˆéºä¼å­ã®å¤‰åŒ–ï¼‰ã‚„ã€ãŒã‚“ã®æ´»å‹•çŠ¶æ³ã‚’çŸ¥ã‚‹ã“ã¨ãŒã§ãã¾ã™ã€‚
*   **å¾ªç’°è…«ç˜ç´°èƒï¼ˆCTCsï¼‰ï¼š** è„³è„Šé«„æ¶²ã®ä¸­ã«ã„ã‚‹ã€ã¾ã‚ŒãªãŒã‚“ç´°èƒã§ã™ã€‚ã“ã‚Œã‚‰ã®ç´°èƒã‚’è©³ã—ãèª¿ã¹ã‚‹ã“ã¨ã§ã€ãŒã‚“ã®èµ·æºï¼ˆã©ã“ã‹ã‚‰æ¥ãŸã®ã‹ï¼‰ã‚’ç‰¹å®šã§ãã‚‹å ´åˆãŒã‚ã‚Šã¾ã™ã€‚

<table border="1">
    <tr>
        <th>æ¤œæŸ»é …ç›®</th>
        <td>ç´°èƒãƒ•ãƒªãƒ¼DNA (cfDNA)</td>
    </tr>
    <tr>
        <th>åˆ†æå†…å®¹</th>
        <td>éºä¼å­å¤‰ç•°ã€DNAã®é‡ã€ãƒ‘ã‚¿ãƒ¼ãƒ³</td>
    </tr>
    <tr>
        <th>æœŸå¾…ã•ã‚Œã‚‹åŠ¹æœ</th>
        <td>ãŒã‚“ã®éºä¼å­æƒ…å ±ã‚’æŠŠæ¡ã—ã€æ²»ç™‚æ–¹é‡ã®æ±ºå®šã«å½¹ç«‹ã¦ã‚‹</td>
    </tr>
</table>

ã“ã®æ¤œæŸ»ã«ã‚ˆã£ã¦ã€ãŒã‚“ã®éºä¼å­å¤‰ç•°ãŒã€å…ƒã®å ´æ‰€ï¼ˆä¾‹ãˆã°è‚ºãŒã‚“ã‚„ä¹³ãŒã‚“ï¼‰ã§ç™ºè¦‹ã•ã‚ŒãŸã‚‚ã®ã¨ç•°ãªã‚‹å ´åˆãŒã‚ã‚‹ã“ã¨ã‚‚ã‚ã‹ã£ã¦ãã¾ã—ãŸã€‚ã“ã‚Œã¯ã€ãŒã‚“ç´°èƒãŒè„³ã«è»¢ç§»ã™ã‚‹éç¨‹ã§ã€éºä¼å­æƒ…å ±ãŒå¤‰åŒ–ã™ã‚‹å¯èƒ½æ€§ãŒã‚ã‚‹ã“ã¨ã‚’ç¤ºå”†ã—ã¦ã„ã¾ã™ã€‚

<h2 id=expert-opinion>å°‚é–€å®¶ã®æ„è¦‹ï¼šæœªæ¥ã¸ã®æœŸå¾…ã¨èª²é¡Œ</h2>

ã€Œæ¶²ä½“ç”Ÿæ¤œã¯ã€è„³è†œè»¢ç§»ã®è¨ºæ–­ã¨æ²»ç™‚ã«ãŠã„ã¦ã€å¤§ããªå¯èƒ½æ€§ã‚’ç§˜ã‚ã¦ã„ã¾ã™ã€‚æ‚£è€…ã•ã‚“ã®è² æ‹…ã‚’è»½æ¸›ã—ãªãŒã‚‰ã€ã‚ˆã‚Šæ­£ç¢ºãªæƒ…å ±ã‚’å¾—ã‚‹ã“ã¨ãŒã§ãã‚Œã°ã€æ²»ç™‚åŠ¹æœã®å‘ä¸Šã«ã‚‚ã¤ãªãŒã‚‹ã§ã—ã‚‡ã†ã€‚ã—ã‹ã—ã€ã¾ã èª²é¡Œã‚‚ã‚ã‚Šã¾ã™ã€‚ä¾‹ãˆã°ã€æ¤œæŸ»ã®ç²¾åº¦ã‚’ã•ã‚‰ã«é«˜ã‚ã‚‹å¿…è¦ãŒã‚ã‚Šã€ã¾ãŸã€å¾—ã‚‰ã‚ŒãŸæƒ…å ±ã‚’ã©ã®ã‚ˆã†ã«æ²»ç™‚ã«æ´»ã‹ã™ã‹ã€ã•ã‚‰ãªã‚‹ç ”ç©¶ãŒå¿…è¦ã§ã™ã€‚æ‚£è€…ã•ã‚“ã«ã¯ã€ã“ã®æŠ€è¡“ãŒã‚‚ãŸã‚‰ã™å¯èƒ½æ€§ã¨ã€ã¾ã è§£æ±ºã™ã¹ãèª²é¡ŒãŒã‚ã‚‹ã“ã¨ã‚’ç†è§£ã—ã¦ã‚‚ã‚‰ã†ã“ã¨ãŒé‡è¦ã§ã™ã€‚ã€

ã€Œã‚‚ã—ã‚ãªãŸãŒã€ã‚ã‚‹ã„ã¯ã‚ãªãŸã®å‘¨ã‚Šã®äººãŒã€é ­ç—›ã‚„åãæ°—ãªã©ã®ç—‡çŠ¶ã«æ‚©ã‚“ã§ã„ã‚‹ãªã‚‰ã€å°‚é–€åŒ»ã«ç›¸è«‡ã™ã‚‹ã“ã¨ã‚’ãŸã‚ã‚‰ã‚ãªã„ã§ãã ã•ã„ã€‚æ—©æœŸç™ºè¦‹ã€æ—©æœŸæ²»ç™‚ãŒã€ã‚ˆã‚Šè‰¯ã„æœªæ¥ã¸ã®ç¬¬ä¸€æ­©ã§ã™ã€‚ã€

<h2 id=conclusion>çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘ï¼š2025å¹´ä»¥é™ã®åŒ»ç™‚ã®æœªæ¥ã¸</h2>

è„³è†œè»¢ç§»ã¯ã€ä¾ç„¶ã¨ã—ã¦æ²»ç™‚ãŒé›£ã—ã„ç—…æ°—ã§ã™ãŒã€æ¶²ä½“ç”Ÿæ¤œã®ç™»å ´ã«ã‚ˆã£ã¦ã€ãã®è¨ºæ–­ã¨æ²»ç™‚ã«æ–°ãŸãªå¸Œæœ›ãŒè¦‹ãˆã¦ãã¾ã—ãŸã€‚2025å¹´ä»¥é™ã€ã“ã®æŠ€è¡“ãŒã•ã‚‰ã«é€²æ­©ã—ã€ã‚ˆã‚Šå¤šãã®æ‚£è€…ã•ã‚“ã«è²¢çŒ®ã™ã‚‹ã“ã¨ãŒæœŸå¾…ã•ã‚Œã¾ã™ã€‚

ã“ã®æƒ…å ±ãŒã€å°‘ã—ã§ã‚‚å¤šãã®æ‚£è€…ã•ã‚“ã¨ãã®ã”å®¶æ—ã®å½¹ã«ç«‹ã¤ã“ã¨ã‚’é¡˜ã£ã¦ã„ã¾ã™ã€‚ãã—ã¦ã€ã“ã®æŠ€è¡“ã®é€²æ­©ãŒã€åŒ»ç™‚ã®æœªæ¥ã‚’æ˜ã‚‹ãç…§ã‚‰ã™ã“ã¨ã‚’ä¿¡ã˜ã¦ã„ã¾ã™ã€‚

ã‚‚ã—ã€ã“ã®æƒ…å ±ã«ã¤ã„ã¦ã€ã•ã‚‰ã«è©³ã—ãçŸ¥ã‚ŠãŸã„ã“ã¨ã‚„ã€ç–‘å•ç‚¹ãŒã‚ã‚Œã°ã€ãŠæ°—è»½ã«ã”è³ªå•ãã ã•ã„ã€‚
</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12355770/" target="_blank">ğŸ‘‰ æŸ¥çœ‹åŸå§‹æ–°è</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>